Elizabeth Omoniyi, MD
Endocrinology, Diabetes & Metabolism · Ada, OKNPI 1194250985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Xeris Pharmaceuticals, Inc. at 25.6% of the total. 2025 is the largest year on record at $757, 2.2 times the $345 reported in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in OK, where the typical reported total is $2,620.
Across 99 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$525
- Insulet Corporation$233
- Tandem Diabetes Care, Inc.$187
- Corcept Therapeutics$170
- Boehringer Ingelheim$150
- Mannkind Corporation$134
- plus $656 from 15 others
What the payments were for
- Food & beverage$2,055100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 29 | $525 |
| Insulet Corporation | 7 | $233 |
| Tandem Diabetes Care, Inc. | 9 | $187 |
| Corcept Therapeutics | 7 | $170 |
| Boehringer Ingelheim | 8 | $150 |
| Mannkind Corporation | 3 | $134 |
| Novo Nordisk | 5 | $119 |
| Amgen | 4 | $76 |
| Antares Pharma, Inc. | 3 | $54 |
| Abbott | 3 | $52 |
| BETA Bionics, Inc. | 4 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Ascensia Diabetes Care US Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $40 |
| Medtronic | 3 | $40 |
| Dexcom, Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $24 |
| Cequr Corporation | 2 | $23 |
| Novartis | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
How this compares
$2,055 in reported general payments places this provider in the 45th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 190 | $237,475 |
| TrulicityDulaglutide | 170 | $228,358 |
| MounjaroTirzepatide | 116 | $183,348 |
| FarxigaDapagliflozin Propanediol | 141 | $142,295 |
| JardianceEmpagliflozin | 72 | $90,273 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $62,680 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 22 | $54,329 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $52,223 |
| Bydureon BciseExenatide Microspheres | 40 | $50,163 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $41,490 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $28,611 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $24,122 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 181 | $21,491 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $19,863 |
| Gvoke Hypopen 2-PackGlucagon | 27 | $16,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $40 | $412,969303 claims |
| Novo NordiskOzempic, Novolog | $119 | $238,923201 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $150 | $96,75984 claims |
| AmgenEvenity (2 Syringes) | $76 | $54,32922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Ada
- Shrina ParekhAda$1K
- Cassie SmithEdmond$629K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Matthew DraelosEdmond$110K
- Christian MangrumOklahoma City$54K
- Vaqar AhmadMidwest City$27K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Robert ScofieldOklahoma City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.